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AbstrACt
Introduction Advances in wearable sensor technology 
now enable frequent, objective monitoring of real- world 
walking. Walking- related digital mobility outcomes (DMOs), 
such as real- world walking speed, have the potential to be 
more sensitive to mobility changes than traditional clinical 
assessments. However, it is not yet clear which DMOs 
are most suitable for formal validation. In this review, we 
will explore the evidence on discriminant ability, construct 
validity, prognostic value and responsiveness of walking- 
related DMOs in four disease areas: Parkinson’s disease, 
multiple sclerosis, chronic obstructive pulmonary disease 
and proximal femoral fracture.
Methods and analysis Arksey and O’Malley’s 
methodological framework for scoping reviews will guide 
study conduct. We will search seven databases (Medline, 
CINAHL, Scopus, Web of Science, EMBASE, IEEE Digital 
Library and Cochrane Library) and grey literature for 
studies which (1) measure differences in DMOs between 
healthy and pathological walking, (2) assess relationships 
between DMOs and traditional clinical measures, (3) 
assess the prognostic value of DMOs and (4) use DMOs as 
endpoints in interventional clinical trials. Two reviewers will 
screen each abstract and full- text manuscript according to 
predefined eligibility criteria. We will then chart extracted 
data, map the literature, perform a narrative synthesis and 
identify gaps.
Ethics and dissemination As this review is limited to 
publicly available materials, it does not require ethical 
approval. This work is part of Mobilise- D, an Innovative 
Medicines Initiative Joint Undertaking which aims to 
deliver, validate and obtain regulatory approval for DMOs. 
Results will be shared with the scientific community 
and general public in cooperation with the Mobilise- D 
communication team.
registration Study materials and updates will be 
made available through the Center for Open Science’s 
OSFRegistry (https:// osf. io/ k7395).
bACkground
For people living with chronic health condi-
tions, walking impairment is associated with 
reduced quality of life,1–4 disability progres-
sion,1 5 6 fall risk,7–9 hospitalisation10 11 and 
mortality.10 11 Research is booming on ther-
apies that can mitigate the high human 
and economic costs of walking impairment. 
However, before these therapies can be 
adopted in clinical practice, their efficacy 
must be established through controlled clin-
ical trials. The endpoint measures used to 
assess these interventions’ efficacy should 
be valid, sensitive, easy to administer and 
representative of real- world function or 
behaviour.12
strengths and limitations of this study
 ► This is the first scoping review to explore existing 
evidence on the discriminant ability, construct valid-
ity, prognostic value and responsiveness of walking- 
related digital mobility outcomes.
 ► A broad review strategy enables identification of 
trends across methods and settings in four chronic 
conditions.
 ► A multidisciplinary team of clinicians, technologists, 
movement specialists and epidemiologists from ac-
ademia and industry will conduct this review.
 ► Terminology and methodology associated with gait 
assessments are diverse and fragmented, posing 
limitations for study identification and synthesis.
 ► Following scoping review guidelines, neither criti-
cal appraisal nor meta- analysis will be conducted, 
limiting our ability to assess the strength of existing 
evidence.
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box 1 review objective and research questions (rQs)
Objective: Map existing evidence describing the discriminant ability, 
construct validity, prognostic value and responsiveness of walking- 
related digital mobility outcomes (DMOs)
 ► RQ1: What differences in DMOs have been identified between the 
four included populations and healthy controls?
 ► RQ2: What is the evidence on the associations between DMOs and 
clinically relevant measures of physical function, health- related 
quality of life, symptoms and disease severity in each of the includ-
ed populations?
 ► RQ3: What is the evidence on the prognostic value of DMOs in each 
of the included populations?
 ► RQ4: In which contexts and for what purposes have DMOs been 
used as endpoints in controlled interventional studies in each of the 
included populations?
Unfortunately, current mobility measures pose critical 
limitations. Clinical trials traditionally employ two types of 
mobility assessments: patient- reported outcome (PROs) 
instruments and clinical gait assessments. PROs enable 
patients to report perceptions of their own mobility in 
a standardised manner,13 though results may be subject 
to recall bias.14–16 Clinical assessments, such as timed 
walking tests, are typically more objective. However, 
many still require clinical interpretation and are subject 
to high inter- rater variability.17 18 For example, Zhang 
et al conducted a sensitivity analysis to demonstrate the 
potential impact of inter- rater variability in clinical trials 
by assessing a trial’s primary outcome, the Expanded 
Disability Status Score (a common measure of function 
and ambulation in multiple sclerosis) in duplicate.19 Dupli-
cated ratings differed in over 30% of patients, affecting 
estimates of treatment effect. Additionally, clinical assess-
ments are often infrequently acquired and may not be 
representative of real- world behaviour.14 20 21 Compared 
with real- world walking, patients consistently walk faster 
and produce higher quality gait patterns during ‘normal’ 
walking in laboratory settings.20 22 23 These challenges 
have prompted calls for more sensitive, reliable mobility 
measures in clinical trials.21 24
Advances in wearable sensor technology now enable 
frequent, objective mobility monitoring. Digital mobility 
outcomes (DMOs) such as gait speed, variability 
and symmetry have been used to quantify real- world 
walking,25–29 and emerging evidence suggests that they 
may be more sensitive to subtle changes than traditional 
instruments.14 21 30–32 While a growing body of evidence 
supports this theory,12 31 33 34 the validity of DMOs is not 
well established.12 14 30 The field’s fragmentation by disease 
area, technology, taxonomy and methodology14 27 35–39 
currently limits our understanding of their potential. To 
date, no overarching view of the clinical utility of DMOs 
exists.14 Thus, this study will map existing evidence on 
walking- related DMOs to assess their suitability for formal 
validation.
study rAtIonAlE And objECtIvEs
This work is part of Mobilise- D, a research programme 
sponsored by the European Union’s Innovative Medi-
cines Initiative Joint Undertaking, which aims to deliver, 
validate and obtain regulatory approval for a suite of 
real- world DMOs.40 41 This study will hone our under-
standing of the contexts and purposes for which DMOs 
might be most effectively used as research instruments. 
Our primary objective is to map the evidence describing 
the discriminant ability, construct validity, prognostic 
value and responsiveness of walking- related DMOs. We 
will focus on four disease areas: Parkinson’s disease (PD), 
multiple sclerosis (MS), chronic obstructive pulmonary 
disease (COPD) and proximal femoral fracture (PFF). 
By mapping the literature and providing a narrative 
synthesis of our findings, we will identify which DMOs 
pose the greatest potential as clinical endpoints.
MEthods And AnAlysIs
Protocol structure
This study employs the scoping review methodology 
developed by Arksey and O’Malley42 and advanced by 
Levac et al.43 Arksey and O’Malley’s framework describes 
six stages of scoping review conduct: (1) identifying the 
research question (RQ), (2) identifying relevant studies, 
(3) selecting studies, (4) charting the data, (5) collating, 
summarising and reporting results and (6) consulting 
with relevant stakeholders. In contrast to systematic 
reviews, which assess the literature to answer narrow RQs, 
scoping reviews explore a research topic from a broader 
perspective. They aim to map the state of evidence in a 
structured yet reflexive manner to identify research gaps 
or assess the feasibility of future systematic reviews.42–44
Here we present a harmonised review strategy strati-
fied by RQ and population. This approach will allow us 
to explore the nuances of DMO research in individual 
disease areas while identifying overarching trends.
stage 1: identifying the rQ
Research questions
To be used as clinical trial endpoints, measures must be 
valid, clinically meaningful and responsive to change. 
Preliminary searches revealed a highly fragmented body 
of literature, with no overarching review describing these 
characteristics. Therefore, this study will map the litera-
ture across four RQs (box 1) in a set of walking- related 
DMOs (box 2). Though DMOs have potential to be used 
in many disease areas, this study will focus on PD, MS, 
COPD and PFF (subsequently referred to as ‘included 
populations’). The Mobilise- D consortium selected these 
disease areas as exemplars for DMO development due 
to their diverse aetiologies of mobility impairment, high 
public health burden and existing evidence base.26 27 45 46
RQ1: discriminant ability
First, we will explore DMOs’ discriminant ability by iden-
tifying studies which compare healthy and pathological 
gait (box 1, RQ1). In this analysis, we will map evidence 
describing differences in DMOs between people with 
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box 2 Walking- related digital mobility outcomes included 
in this review*
spatial parameters
 ► Step length (magnitude, variability, symmetry).
 ► Stride length (magnitude, variability).
 ► Step width (magnitude, variability).
temporal parameters
 ► Cadence (magnitude, variability).
 ► Step time (magnitude, variability, symmetry).
 ► Stride time (magnitude, variability).
 ► Stance time (magnitude, variability, symmetry).
 ► Swing time (magnitude, variability, symmetry).
 ► Single support time (magnitude, variability, symmetry).
 ► Double support time (magnitude, variability).
spatiotemporal parameters
 ► Gait speed (magnitude, variability).
 ► Stride speed (magnitude, variability).
volume of walking
 ► Walking time.
 ► Step count.
 ► Number/duration of walking bouts.
*A narrative definition of each parameter is provided in online supplementary 
file 1.
one of the four target diseases and healthy controls. We 
hypothesise that differences in some, but not all, DMOs 
will emerge between healthy individuals and the four 
included populations.
RQ2: construct validity
We will then gather evidence informing the construct 
validity of DMOs. We hypothesise that DMOs will exhibit 
moderate to strong associations with measures that assess 
physical function, such as balance tests, and weaker asso-
ciations with measures which are not directly related to 
physical function. To test this, we will map cross- sectional 
relationships (ie, assessed across a study population at a 
single timepoint) between DMOs and clinically relevant 
measures of disease severity, physical function, health- 
related quality of life and other symptoms in each of the 
included populations.
RQ3: prognostic value
Next, we will map the evidence that informs the prog-
nostic value of DMOs (ie, their ability to predict future 
health outcomes). We will do this by mapping longi-
tudinal associations between DMOs measured at base-
line and clinically relevant health outcomes assessed at 
follow- up. We hypothesise that DMOs will exhibit prog-
nostic value similar to that established for traditional 
measures of mobility.10 47–49
RQ4: responsiveness to intervention
Finally, we will gather evidence that informs the respon-
siveness of DMOs to intervention. We expect that the use 
of DMOs as endpoints in interventional studies will be 
rare.34 However, we hypothesise that, when they are used, 
DMOs will be responsive to interventions which improve 
physical function or reduce mobility- limiting symptoms. 
To this end, we will map the use and responsiveness of 
DMOs as endpoints in controlled interventional studies.
Definitions and study scope
Preliminary searches revealed that an exhaustive review is 
infeasible due to inconsistent terminology and reporting 
practices. Thus, we do not necessarily intend to produce 
an exhaustive list of all previous studies. Instead, we 
will adopt a semistructured approach to map clinically 
relevant trends across this large, fragmented body of 
literature. To do this, we will limit some dimensions of 
study scope to lengthy lists (ie, the DMOs, the measures 
assessed in RQ2 and the outcomes assessed in RQ3) and 
will apply basic quality thresholds (ie, a minimum number 
of participants). This approach allows us to remain inclu-
sive with regard to terminology and methodology while 
ensuring feasibility. The decisions used to set this scope 
are described below. Because understanding of seemingly 
common terms differs across disciplines, defining the 
concepts addressed by this review was not trivial. There-
fore, our operational definitions of key concepts such as 
‘mobility’, ‘walking’, ‘real- world’ and ‘DMOs’ are clearly 
defined in box 3.
Mobility and real-world walking
According to the International Classification of Func-
tioning, Disability and Health (ICF), ‘mobility’ is a 
complex concept, inclusive of both functional ability 
and social participation. ‘Walking’ represents a distinct 
construct encompassed by this broader concept of 
mobility. In this review, we adhere to the definition of 
‘walking’ adopted by the Mobilise- D consortium (box 3). 
Our ultimate aim is to explore the utility of DMOs to 
characterise ‘real- world’ walking. However, until recently, 
studies on gait parameters were largely confined to clin-
ical settings. While methodologically different, laboratory 
or clinic- based measurements may still provide insight 
into DMOs’ potential as real- world measures. Therefore, 
we will include walking- related DMOs measured in any 
setting, real- world or otherwise. This inclusive approach 
will also enable us to compare DMOs measured during 
real- world walking, supervised tests and scripted walking.
Digital mobility outcomes
Theoretically, DMOs could include any digital measures 
encompassed by the ICF definition of ‘mobility.’ However, 
our scope will be limited to a set of 32 DMOs associated 
with walking, (box 2) since walking is the primary focus of 
the Mobilise- D project. This list was compiled in consulta-
tion with mobility experts, technologists and clinicians in 
the four disease areas. It includes spatiotemporal parame-
ters characterised in three widely accepted factor analyses 
of gait50–53 and parameters associated with daily volume 
of walking. This list excludes non- linear gait and dynamic 
balance measures, such as Lyapunov exponents54 55 and 
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box 3 operational definitions of key concepts adopted for 
this review
Mobility
According to the International Classification of Functioning, Disability 
and Health (ICF), ‘mobility’ is defined as moving by (a) changing body 
position or location or by transferring from one place to another, (b) 
by carrying, moving or manipulating objects, (c) by walking, running or 
climbing and (d) by using various forms of transportation.65
Walking
Per the Mobilise- D consortium, Human walking is a method of locomo-
tion and is defined as initiating and maintaining a forward displacement 
of the centre of mass in an intended direction involving the use of the 
two legs which provide both support and propulsion. The feet are repet-
itively and reciprocally lifted and set down whereby at least one foot is 
in contact with the ground at all times.66 67 Walking with walking aids is 
included in this definition. Walking is made up of walking bouts and is 
equivalent to taking steps/stepping forward (thus stepping in place does 
not constitute walking) and is defined as starting from initial contact for 
the initial step until ending with full floor contact of the foot making the 
last step.68
real- world walking
Per the Mobilise- D consortium, ‘Real world’ relates to the context in 
which walking takes place—that is free- living, unsupervised, uncon-
trolled and non- standardised. As such, it is unscripted as there are no 
instructions to the subject. Real- world actions occur in non- simulated 
everyday situations in unconstrained environments with minimal con-
sciousness of being tested. It is equivalent to actions at home or in the 
community over continuous periods of time.23 … Real- world walking 
is distinct from laboratory- based,69 supervised (fully controlled and 
observed) and semi- controlled (walking ‘freely’ but with supervision) 
tests. It also is different from scripted or instructed walking, which can 
take place in the home or lab.
digital mobility outcomes
Digital mobility outcomes are digitally measured mobility parameters 
used to assess an individual’s health status, such as spatiotemporal 
gait parameters, walking bout characteristics and physical activity. In 
this case, ‘digital’ measures refer to those objectively derived from elec-
tronic systems, as opposed to qualitative, paper- based or self- reported 
measures.
Clinically relevant measures and outcomes
‘Clinically relevant’ measures and outcomes as those that are routinely 
and broadly used either in clinical practice or in major pharmaceutical 
or epidemiological studies. ‘Measures’ refer to instruments or tests that 
assess an aspect of a patient’s health at a single point in time, while 
‘outcomes’ refer to identified changes in health status that result from 
the handling of a health problem.70
detrended fluctuation analyses,56 due to the emergent 
nature of their evidence base. Though we also consider 
digital measures of physical activity to be DMOs, phys-
ical activity measures indirectly related to walking, such 
as daily energy expenditure or activity intensity, are also 
out of scope. This is because physical activity represents a 
related, yet broader construct.57–59
Clinically relevant measures and outcomes
To ensure study scope remains clear and manageable, lists 
of included measures (46 general, 67 disease- specific) and 
outcomes (13 general, 16 disease- specific) were defined 
a- priori in consultation with technical and clinical subject 
matter experts on the Mobilise- D research team. While 
these lists are not exhaustive, they contain the most 
important measures and outcomes used clinically in each 
of the four populations (online supplementary file 1). In 
alignment with the reflexive approach outlined by Arksey 
and O’Malley,42 we defined a systematic method to amend 
these lists if additional instruments meeting these criteria 
are identified during study conduct.
stage 2: identifying relevant studies
This study will be conducted between November 2019 and 
December 2020. We will include peer- reviewed and grey 
literature, including journal articles, reports, research 
letters, conference papers, doctoral theses and other publi-
cations reporting original results. MEDLINE, CINAHL, 
Scopus, Web of Science, EMBASE, IEEE Digital Library 
and the Cochrane Library will be searched for eligible peer- 
reviewed literature. ACM Digital Library, ProQuest Disser-
tations, Open Grey and the National Information Center’s 
Health Services Research Projects in Progress Database 
will be searched to identify relevant grey literature. We 
will supplement these searches with the first 100 results on 
Google Scholar for each population, with results first sorted 
by relevance and then by time. Though we will limit studies 
based on availability of English- language abstracts, we will 
include full- text articles written in any language spoken by 
members of the Mobilise- D consortium. Additional sources 
will include manual searches of reference lists and publi-
cations from the review team’s private libraries. Based on 
subject matter expert recommendations, the search will be 
limited to studies published during or after 1999. This time 
frame reflects advances in gait monitoring technology in 
the early 2000s and is supported by the findings of previous 
systematic reviews.60–62
Due to the diverse terminology associated with digital 
technologies and gait assessment, we opted for a broad 
search strategy which was agnostic to methodology or 
technology. This strategy was developed through collab-
oration between the research team and an experienced 
information specialist. Each search includes terms 
related to walking assessments and the four populations 
according to the structure (walking terms) AND (popula-
tion terms). The proposed search strategy for EMBASE is 
provided in online supplementary file 2.
Study design, review conduct, records of deduplica-
tion, reference exclusion and individual author contribu-
tions will be managed in DistillerSR (Evidence Partners, 
Ottawa, Canada). Initially, references will be compiled 
in Endnote (Clarivate Analytics, Boston, USA), and the 
final review libraries will be compiled in Mendeley (Else-
vier B.V., Amsterdam, The Netherlands), an open- access 
reference management software.
stage 3: study selection
Study selection process
Study selection will include three steps: piloting, title 
and abstract screening and full- text review. All reviewers 
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will receive training on scoping review conduct prior 
to abstract screening. All reviewers will pilot eligibility 
criteria on a random set of 50 abstracts to ensure consis-
tency. Clarifications will be made as necessary. Agreement 
with the lead reviewer (AMP) will then be monitored 
on an additional 100 abstracts per reviewer at the onset 
of the screening process. In the full- text review stage, a 
similar process will be repeated on 15 full- text articles. 
Prior to screening, duplicate studies will be identified by 
comparing titles, authors, publication years and abstracts. 
If additional duplicates are identified during full- text 
review or data extraction, they will be excluded. Multiple 
sources reporting on the same study will be linked and 
analysed as one study during synthesis.
Up to three reviewers will independently screen each 
abstract for inclusion according to predefined eligibility 
criteria. Reviewers will use detailed reference sheets 
to ensure a uniform approach to screening (online 
supplementary file 3). Abstracts will proceed to full- text 
review if any single reviewer determines that it meets 
eligibility criteria. If the first reviewer includes the 
abstract, it will proceed automatically to full- text review 
and will not undergo a second screening. Agreement of 
two reviewers will be required to exclude an abstract. 
In cases of high uncertainty, reviewers will be able to 
request a third screening by the lead reviewer (AMP). 
Agreement will be assessed between each reviewer and 
the primary reviewer via Cohen’s Kappa and as a group 
via Fleiss’ Kappa. In contrast to Cohen’s Kappa, which 
calculates agreement of two independent raters, Fleiss’ 
Kappa statistic assesses reliability between any number 
of raters giving categorical ratings to a fixed number 
of items.63 We anticipate that disease- specific knowl-
edge will be necessary for full- text eligibility assessment. 
Thus, studies will be manually segmented by disease 
area during abstract screening. Consistent with the 
reflexive nature of scoping reviews, a second round of 
abstract screening may be conducted if additional eligi-
bility criteria are identified during the study process or if 
disease- specific knowledge is required to assess abstract 
eligibility. This round will follow the same procedure as 
the original screening stage.
Two reviewers will then independently assess each full- 
text article for inclusion according to predefined eligi-
bility criteria. Reason(s) for exclusion will be documented 
and agreement will be calculated. Reviewers will resolve 
disagreements through discussion. If no consensus can 
be reached, a senior team member will review the article 
and make the final determination.
Eligibility criteria
To be included, studies must address one of our RQs with 
respect to an included DMO in one of our four popu-
lations. Detailed criteria and considerations regarding 
study design, included DMOs and patient populations are 
provided below. We also provide operational definitions 
of ‘addressing a RQ’.
Study design and setting
Studies must present original data to be eligible for 
inclusion. To prevent crowding of results, we will also 
require that a minimum of 10 individuals per study arm 
are included in a relevant analysis. Though these two 
criteria naturally exclude reviews, case studies and case 
series, any other design is theoretically eligible. However, 
not all study designs are capable of addressing all four 
RQs. Therefore, RQ- specific study design considerations 
are also provided as appropriate below. We will include 
studies and walking assessments conducted in any setting 
(laboratory, in- clinic, real- world).
DMOs, technologies and methods
For reasons described above, this review will be limited to 
the DMOs summarised in box 2. We will include DMOs 
produced through any digital or electronic measure-
ment method, including wearable sensors, instrumented 
walkways or treadmills, optometric systems, force plates, 
mobile phones, stopwatches and pedometers, among 
others. We will include DMOs measured during any test 
or walking condition that includes or simulates normal, 
over- ground walking. This includes walking at any speed 
(ie, top- speed, self- selected), any start conditions (eg, 
static start or rolling start), single- task or dual- task walking, 
straight or curvilinear walking. Walking may be free or 
scripted, measured indoors or outdoors, supervised or 
unsupervised, on a treadmill, walkway or over- ground on 
any course regardless of shape or length. Because tradi-
tional timed gait speed tests use stopwatches (an included 
technology) to measure gait speed (an included DMO), 
they will also be included. However, we will exclude 
testing conditions that purposefully alter participants’ 
normal gait patterns, such as stepping in time to music. 
We will also exclude analyses limited to climbing, turning 
and analyses of single steps, such as the recovery step after 
a push.
During pilots, these criteria were consistently inter-
preted in most cases. However, specific challenges arose 
regarding the eligibility of timed clinical assessments that 
include periods of walking. For example, some authors 
refer to the timed up and go (TUG) test as a measure 
of gait speed. However, the TUG measures the time 
required to rise from a seated position, walk around 
a course and return to a seated position.64 In popula-
tions with mobility impairment, time spent standing and 
sitting may not be trivial. Thus, the TUG encompasses 
multiple constructs. To ensure consistency, it was neces-
sary to define explicit eligibility criteria for common tests 
such as the TUG. These criteria were developed based 
on literature searches and in consultation with mobility 
experts (authors LR, JGA, TT, MP, AY, LL and BS), and 
are described with rationale in online supplementary file 
1. Generally, we will include timed gait speed tests, such 
as the 10- m walk, but will exclude timed tests that aggre-
gate or assess constructs other than gait speed. However, 
studies may still be included if DMOs were specifically 
assessed during the walking portions of excluded tests. 
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For example, if the TUG was instrumented and gait 
speed or other DMOs were measured during the walking 
portion of the test, this analysis is included though the 
total time to complete the TUG is not.
Patient populations
To be eligible, studies must include patients with 
a confirmed diagnosis of one of the four included 
conditions: PD, MS, COPD and PFF. In this context, a 
‘confirmed diagnosis’ is one made by a clinician based on 
the relevant diagnostic criteria at the time of the study’s 
publication. Further detail is provided in online supple-
mentary file 1. No eligibility criteria on age range, disease 
severity level or subtype will be applied except for PFF 
populations, which will be limited to adults 65 years of 
age or older. Studies with mixed populations will also be 
included if a subanalysis is conducted on an included 
population.
Addressing an RQ
Though we do not pose specific methodological require-
ments for inclusion, not all statistical methods and study 
designs are capable of addressing each RQ. For example, 
case–control designs cannot assess responsiveness to 
intervention (RQ4), though they can be used to compare 
pathological and healthy gait (RQ1) and assess relation-
ships between DMOs and clinically relevant measures 
(RQ2). In light of these methodological distinctions, each 
of our RQs could be viewed as separate—though highly 
inter- related—reviews, harmonised under a common 
strategy. With this in mind, we will map the literature 
separately for each RQ and must therefore set specific 
criteria to determine whether studies address an RQ.
Studies will be eligible to address RQ1 if they compare 
an included DMO between healthy controls and one of 
the included populations. No other RQ- specific eligibility 
criteria will be applied.
Studies will be eligible to address RQ2 if they assess the 
relationship between an included DMO and an included 
measure in one of the four populations at a single time-
point (ie, a cross- sectional analysis). The list of included 
measures, defined a- priori, is comprised of widely used 
measures of disease severity, health- related quality of life, 
physical function, cognition, mental health and other 
factors (online supplementary file 1). We will include any 
type of statistical or qualitative analysis and set no specific 
study design requirements, since such an analysis could 
be conducted within any study design.
Studies will be eligible to address RQ3 if they assess a 
relationship between an included DMO measured at base-
line and an included outcome assessed at follow- up (ie, a 
longitudinal analysis). Included outcomes are described 
in online supplementary file 1. Studies must be longitu-
dinal to address this RQ, though we set no further criteria 
on the basis of methodology or study duration.
Studies will be eligible to address RQ4 if they use an 
included DMO as an endpoint in a controlled inter-
ventional study in an included population. Published 
protocols of controlled trials will be indexed for future 
analysis. Studies will not be excluded on the basis of inter-
vention type, duration or follow- up frequency. We will 
exclude uncontrolled studies from this RQ, since they are 
particularly susceptible to placebo effect and other biases. 
However, uncontrolled interventional studies may still be 
included in the review if they conduct an analysis which 
addresses any of the other RQs. We pose no other meth-
odological criteria for RQ4.
At the abstract stage, studies will be included in full- text 
review if they could possibly have conducted an included 
analysis, since relevant analyses are not consistently 
reported at the abstract level. Analyses addressing each 
RQ will be identified during full- text screening.
Addressing unforeseen eligibility criteria
Arksey and O’Malley’s framework specifically allows for 
flexibility in the review process,42 as appropriate scope and 
eligibility criteria may not be initially clear when reviewing 
a previously unmapped research area. As research on gait 
is rapidly evolving, it may be necessary to adjust our eligi-
bility criteria and lists of included walking conditions, 
measures and outcomes. If initial findings warrant adjust-
ments, a proposal will be submitted to a team of project 
leads who will make the final determination on how to 
adjust eligibility criteria. Adjustments will be applied to all 
identified studies and reported accordingly.
stage 4: charting the data
Data extraction
Data collection forms will be developed through iterative 
review with the research team and further refined through 
expert feedback. Forms will capture all relevant study 
data and contextual information while ensuring adequate 
flexibility to capture emerging themes. Prior to initiating 
data extraction, the form will be tested by reviewers on a 
random sample of at least five studies. Additional modi-
fications to the form identified through this pilot will be 
reviewed and approved by the research team.
Data extraction will be conducted independently by 
two reviewers in DistillerSR. A preliminary set of data 
items is included in table 1, which will be further speci-
fied following feedback from the disease- specific review 
groups. Studies’ corresponding authors will be contacted 
if clarification is required. Disagreements will be resolved 
through discussion. If no consensus can be reached, a 
third, senior member of the research team will make the 
final determination.
Revising data items
If additional relevant data items are identified during 
the review process, they will be submitted to the team of 
project leads to decide whether and how to adjust the 
data extraction form. If included, the new data items will 
be extracted from all included studies.
stage 5: collating, summarising and reporting the results
The evidence addressing each RQ will be mapped and 
analysed through narrative synthesis. Findings will be 
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Table 1 Preliminary data items to extract
Data items Associated questions
Publication details (all research questions)
  Authors and affiliations Who conducted the research?
  Type In what type of literature was the study published? (Journal, grey literature, conference abstract)
  Year When was the study published?
  Country/region In which geographic region(s) did the study take place?
General details (all research questions)
  Study design What was the study’s design?
  Study aims What were the study’s aims?
  Population What population was studied? Were there any specific inclusion/exclusion criteria such as 
disease severity, subtype or age?
  Study size How many people participated in the study?
  Included DMOs Which DMOs were measured? How and in what setting were the DMOs measured?
Research question 1
Study design Were patients and controls matched or are the groups comparable with respect to appropriate 
criteria (height, age, sex)? Was gait analysis controlled for gait speed? Did the study focus on a 
specific subgroup or population?
Differences in DMOs What differences in DMOs occurred (or did not occur) between the four included populations 
and healthy controls?
Did these differences reach statistical significance?
Research question 2
  Analytical methods How did the authors measure the relationship between clinically relevant measures and DMOs? 
What association measure was used?
  Clinically relevant measures What clinically relevant measures were studied?
  Relationship strength What was the strength of the reported relationship between the measure and the DMO? Was the 
association statistically significant?
Research question 3
  Model description Does the study report a multivariate analysis, a prediction model, a model based on machine- 
learning? Which covariates were included in the model? Which analytical methods were used?
  Clinically relevant outcomes What clinically relevant outcomes were studied to assess the DMO’s prognostic value?
  Prognostic value Did the DMO provide prognostic value with respect to the studied outcome?
Research question 4
  Intervention type What intervention was studied?
  Study endpoints Was the DMO used as a primary, secondary or exploratory endpoint? What other primary, 
secondary and exploratory endpoints were measured?
  Success Was there a change in the primary endpoint between groups?
  Ability to detect change Was the DMO able to detect a change due to the intervention (if a change occurred)?
DMO, digital mobility outcomes.
compiled in tables and figures where appropriate. Narra-
tive synthesis will also be used to make comparisons 
between populations, disease subtypes and measurement 
conditions. We will also identify gaps in the evidence to 
inform areas of future research. Reporting will adhere 
to the Preferred Reporting Items for Systematic reviews 
and Meta- Analyses extension for Scoping Reviews44 
with the exception of risk of bias and evidence strength 
assessments, which are not mandatory and will not be 
conducted in this study.42–44
stage 6: consultation
Levac et al recommend that research teams involve stake-
holders throughout review conduct, as stakeholders can 
provide nuanced insights beyond those reported in the 
literature.43 The long- term goal of Mobilise- D is to vali-
date and qualify DMOs that can be used to assess mobility 
in clinical trials. While such an undertaking involves a 
number of diverse stakeholders, the present work could 
be most influenced by the perspectives of industry, 
patients and clinical researchers.
Patient and public involvement
Mobilise- D’s pharmaceutical industry partners, patient advi-
sory board and scientific advisory board will be consulted 
during review conduct and data analysis. Industry partners 
reviewed the RQs to ensure relevance for clinical trials and 
regulatory qualification. Patients were not directly involved 
in the design of this review. However, the Mobilise- D patient 
advisory board and scientific advisory board will be engaged 
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during data analysis and reporting to ensure analyses align 
with the priorities of those groups.
discussion and limitations
Current literature on DMOs represents a diverse set of 
research perspectives, resulting in a rich—though frag-
mented—body of literature. Therefore, we devised a broad 
review strategy, attempting to map the literature across 
clinical and technological divides. However, this strategy 
raises challenges of feasibility; our searches yielded tens of 
thousands of references. Though carefully designed, these 
searches may still be limited due to inconsistent termi-
nology and reporting practices. Due to our broad strategy, 
we expect a high degree of heterogeneity in our results. 
Though challenging, this heterogeneity is also a strength, as 
it enables us to compare DMOs measured with various tech-
nologies under diverse walking conditions. Therefore, we 
predefined some of the relationships we intend to map (ie, 
the DMOs, measures and outcomes) while leaving other 
aspects of our scope open (ie, methodology, walking condi-
tion and setting). We have also applied minimal criteria 
such as study size, excluding the smallest studies which 
would crowd results. Where appropriate, we will carefully 
employ the reflexive strategies afforded by scoping review 
methodology to ensure that the items defined a- priori 
do not impart bias. For these reasons, this study should 
be interpreted as identifying clinically relevant trends 
within the existing literature, rather than as an exhaus-
tive review. We will not conduct critical appraisal or meta- 
analysis, limiting our ability to assess the strength of existing 
evidence. However, we will identify topics ripe for systematic 
review, which should be conducted in future work.
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